Results: 2

1.
Figure 2

Figure 2. From: Racial Disparities in Cancer Survival Among Randomized Clinical Trials Patients of the Southwest Oncology Group.

Forest plot of the associations between survival and race among premenopausal and postmenopausal breast cancer patients by estrogen receptor (ER) status. A vertical line representing no effect (HR = 1) is shown. The area of each square is proportional to the sample size for the subgroup, and the length of the whiskers indicate the 95% confidence intervals. P values for interaction are shown. The Wald χ2 test statistic for the effect of race on survival in the multivariate setting is also included. All statistical tests were two-sided. HR = hazard ratio; AA = African American.

Kathy S. Albain, et al. J Natl Cancer Inst. 2009 July 15;101(14):984-992.
2.
Figure 1

Figure 1. From: Racial Disparities in Cancer Survival Among Randomized Clinical Trials Patients of the Southwest Oncology Group.

Kaplan–Meier overall survival plots for African American patients vs patients of all other races or ethnic groups. A) Premenopausal adjuvant breast cancer. B) Postmenopausal adjuvant breast cancer. C) Advanced ovarian cancer. D) Advanced prostate cancer. The number of patients at risk, the number of deaths, the 10-year survival estimate, and median survival estimate are presented. The Wald χ2 test statistic for the effect of race on survival in the multivariable setting was also included. All statistical tests were two-sided. The 10-year overall survival estimates and the corresponding 95% confidence intervals (CIs) by race (all other patients vs African American patients, respectively) for each disease group are as follows: 77% (95% CI = 76% to 79%) vs 68% (95% CI = 62% to 75%) for premenopausal adjuvant breast cancer, 62% (95% CI = 60% to 64%) vs 52% (95% CI = 47% to 58%) for postmenopausal adjuvant breast cancer, 17% (95% CI = 14% to 19%) vs 13% (95% CI = 3% to 22%) for advanced ovarian cancer, and 9% (95% CI = 8% to 11%) vs 6% (95% CI = 3% to 8%) for advanced prostate cancer. The median overall survival estimates and the corresponding 95% confidence intervals by race (all other patients vs African American patients, respectively) for each disease group are as follows: not reached for premenopausal adjuvant breast cancer, 13.5 years (95% CI = 12.9 to 14.2 years) vs 10.2 years (95% CI = 9.1 to 12.0 years) for postmenopausal adjuvant breast cancer, 2.3 years (95% CI = 2.1 to 2.5 years) vs 1.3 years (95% CI = 1.1 to 1.8 years) for advanced ovarian cancer, and 2.7 years (95% CI = 2.5 to 2.9 years) vs 2.2 years (95% CI = 2.0 to 2.4 years) for advanced prostate cancer. Follow-up survival was truncated at 20 years for consistent presentation between panels. AA = African American.

Kathy S. Albain, et al. J Natl Cancer Inst. 2009 July 15;101(14):984-992.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk